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Smoking and Psoriasis:  
From Epidemiology to Pathomechanisms
Luigi Naldi1 and Santo Raffaele Mercuri2
Smoking is a well-established environmental risk factor for psoriasis. It should be 
carefully considered in genetic studies because smoking can modify risk estimates 
for genetic markers. Genome-wide association studies may facilitate the analysis 
of genetic–environmental interaction in psoriasis.
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Multifactorial heredity, the interaction 
between genetic predisposition and envi-
ronmental factors, is hypothesized to 
cause several chronic inflammatory dis-
orders, including psoriasis. According to 
this model, susceptibility for the develop-
ment of psoriatic lesions depends on both 
genetic and extragenetic predisposing 
factors, which are shared by the whole 
skin (“pre-psoriasis”). Disease expression, 
in terms of visible lesions, is influenced 
by extragenetic precipitating or initiating 
factors. Smoking and a high body mass 
index (BMI) are well-established environ-
mental predisposing factors for psoriasis 
(La Vecchia et al., 2005).
Environmental influences should be 
carefully considered in genetic studies 
because they can modify the effects of 
genetic factors (Figure 1). This consid-
eration has commonly been given only 
marginal importance in the genetic stud-
ies of psoriasis, but the report by Duffin 
et al. (this issue) is a welcome departure. 
This paper presents evidence that poly-
morphisms in the IL13/IL4 region (espe-
cially rs1800925*T) may be associated 
with protection from developing psori-
atic arthritis and that this effect may be 
abrogated by smoking. It is unclear from 
the data presented whether smoking per 
se was associated with psoriatic arthritis.
Genetic–environmental interactions 
involving smoking have been proposed 
in other studies of patients with psoria-
sis. In a letter to this journal, a stronger 
association between smoking and pso-
riasis in subjects with a nonvariant 
CYP1A1 genotype has been presented, 
suggesting that sequence variation in 
genes coding for phase 1 and II enzymes, 
including members of the cytochrome 
P450 (CYP) family, may alter individual 
susceptibilities to the development of 
psoriasis in smokers, similar to the effects 
documented in cancer and coronary 
artery disease (Krämer and Esser, 2006). 
In another study, the risk of psoriasis for 
smokers with HLA-Cw6 increased about 
11-fold over that for nonsmokers without 
HLA-Cw6 (Jin et al., 2009). In principle, 
these studies point to possible multiple 
actions (and interactions) of smoking in 
psoriasis. However, drawbacks of these 
studies are their limited statistical power 
and their failure to document significant 
heterogeneity across the strata of smok-
ing status, despite variations in risk point 
estimates. This underlines the difficul-
ties in studying genetic–environmental 
interactions and the need for very large 
sample sizes (on the order of thousands 
of individuals rather than hundreds) to 
obtain reliable estimates.
Current genome-wide association 
studies using gene chips, large sample 
sizes, and case–control designs, instead 
of linkage analysis, may facilitate the 
investigation of genetic–environmental 
interactions and thereby address ques-
tions about disease pathomechanisms. 
One disadvantage to such studies is that 
they may result in large numbers of hints, 
which then require validation studies.
cigarette smoking  
as a complex risk factor
In principle, smoking might influence the 
pathomechanisms of psoriasis in many 
ways. For example, it may accelerate the 
formation of autoantigens in the skin or 
trigger innate immunity (Sopori, 2002). 
Alternatively, genes involved in behav-
iors associated with smoking and tobac-
co dependence may be the real players.
Tobacco smokers are exposed to a 
cocktail of more than 4,000 chemicals, 
which makes it difficult to identify agents 
responsible for tobacco’s wide-ranging 
effects, both detrimental and otherwise 
(Table 1). Nicotine is the principal alka-
loid in tobacco. It is rapidly absorbed 
through the lungs, skin, and gut and 
is metabolized mainly by the liver to 
cotinine and other metabolites, some 
of which are also pharmaco logically 
active. Nicotine exerts its effects by 
activating several subtypes of nicotinic 
table 1. main chemicals  
in tobacco smoke 
Particulate phase
Polycyclic aromatic hydrocarbons
N-heterocyclic amines
Hydroquinone
Nicotine
Phenol, cresol
Naphtylamine
Benzo(a)pyrene
Indole, carbazole
Trace metals (e.g., arsenic)
Vapor phase
Carbon monoxide
Hydrocyanic acid
Acetaldehyde
Acrolein
Ammonia
Formaldehyde 
Nitrogen oxides
Nitrosamines
Hydrazine
Vinyl chloride
The particulate and vapor phases are described 
operationally as fractions of cigarette smoke 
that are retained or passed through a Cambridge 
filter, respectively.
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acetylcholine receptors (nAChRs), 
which are classically found in the ner-
vous system and adrenal medulla, but 
which have also been identified in 
nonneuronal tissue, such as keratino-
cytes in skin, bronchial epithelium, and 
cells involved in inflammation, such as 
monocytes, dendritic cells, and micro-
glial cells. Interaction of nicotine with 
nAChRs results in an initial transient 
stimulation of ganglionic transmission, 
followed by a more persistent depres-
sion (biphasic effect) and the release 
of catecholamines from the adrenal 
medulla and post ganglionic sympathetic 
neurons. The effect of nAChRs on non-
neurologic tissue such as keratinocytes 
and monocytes is less clear, but in the 
former they might facilitate cell-to-cell 
communication, keratinocyte adhesion, 
and upward migration in the epidermis, 
and in the latter they have an immuno-
modulatory effect. Other components 
of tobacco smoking have been related 
to inflammatory and vascular events. 
For example, acrolein, an unsaturated 
aldehyde, affects neutrophil function, 
whereas chronic exposure to benzo(a)
pyrene induces dose-related decreases 
in the mass and cellularity of lymphoid 
tissue (Sopori, 2002). As confirmed in 
a recent meta-analysis, the effects of 
smoking might also be modulated by 
gender, with females at higher risk com-
pared with males for overall morbidity 
and mortality associated with smoking 
at both low and high levels (Mucha et 
al., 2006). This potential gender effect 
should be taken into account in genetic 
analyses and interaction studies.
Smoking and immune-related disease
Cigarette smoking is a risk factor for more 
than two dozen diseases, and it is the 
single greatest cause of preventable mor-
tality worldwide. In addition to its well-
known association with cardiovascular 
disease, chronic obstructive pulmonary 
disease, peptic ulcer, and several cancers 
(especially but not limited to those of the 
respiratory tract), smoking appears to be 
associated with a number of inflamma-
tory immune system–related diseases 
(Sopori, 2002).
Passive exposure to cigarette smoke 
both in utero and during early life 
increases individuals’ subsequent risk of 
developing asthma. Moreover, it is now 
recognized that patients with asthma 
who smoke have an impaired response 
to treatment with corticosteroids. It 
has been proposed that interleukin-1 
receptor antagonist gene poly morphism 
rs2234678 and polymorphisms in 
IL13 interact with maternal smoking to 
increase the risk of childhood asthma 
(von Mutius, 2009).
Smoking is associated with an 
increased risk of Crohn’s disease and 
also has a detrimental effect on its clini-
cal course. In contrast, it decreases the 
risk of ulcerative colitis and, possibly, pri-
mary sclerosing cholangitis. It has been 
suggested that Crohn’s disease is caused 
by an impaired host response to luminal 
bacteria; the documented association of 
Crohn’s disease with mutations in the 
CARD15 (NOD2) gene, which seem to 
be associated with decreased produc-
tion of antimicrobial peptides, supports 
this theory. Smoking in Crohn’s disease 
might further compound any deficiency 
in the host response to luminal bacteria 
(Thomas et al., 2005).
Despite their reduced immunoglobulin 
levels, smokers have increased levels of 
autoantibodies, notably antinuclear rheu-
matoid factors (Sopori, 2002). The dura-
tion and intensity of smoking have been 
linked to a corresponding development 
of rheumatoid arthritis, with an especially 
high risk in postmenopausal women. 
Smoking has also been associated with 
an increase in both the severity of rheu-
matoid arthritis and the disease activity. A 
Swedish population-based case–control 
study has documented that the risk of 
developing rheumatoid factor-positive 
disease substantially increased in smok-
ers carrying double copies of the HLA 
DRB1 shared epitope (relative risk (RR) 
= 15.7) compared with smokers with no 
copies of these genes (RR = 2.4). Recent 
research has also demonstrated additive 
and multiplicative interactions between 
PTPN22 and heavy cigarette smoking 
(Oliver and Silman, 2009).
An excess risk of more than 10-fold in 
tobacco smokers has been documented 
for discoid lupus erythematosus (DLE). 
In addition, DLE and subacute cutane-
ous lupus erythematosus patients who 
are smokers are less likely to respond 
to antimalarial therapy than are non-
smokers (40% vs. 90% response rate). 
A meta-analysis of nine studies, includ-
ing seven case–control and two cohort 
investigations, gave a summary RR for 
systemic lupus erythematosus in smokers 
of about 1.50 (95% confidence interval = 
1.09–2.08) (La Vecchia et al., 2005).
At variance with rheumatoid arthritis, 
no clear documentation of an association 
of psoriatic arthritis with smoking has been 
produced. Tobacco smoking has been 
strongly associated with palmoplantar 
pustulosis (La Vecchia et al., 2005).
the genetics of smoking habits
Both environmental and genetic 
influ ences on tobacco dependence 
exist, and these factors, which affect 
behavior, may, in turn, play a role in 
Genetic factors
Individual at high risk of 
developing psoriasis phenotype
Environmental factors;
smoking status
Smoker Nonsmoker
Disease induction 
by smoke
Risk of disease 
increased further
Disease protection
by smoke
Risk of 
disease reduced
Risk of disease 
remains high
Figure 1. risk estimates and interaction between smoking and genetic factors
|Smoking may affect psoriasis by more than one mechanism. 
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the develop ment of smoking-related 
diseases. Low socioeconomic status, 
peer smoking, and maternal smoking 
during pregnancy are well-documented 
environmental factors that affect smoking 
behavior. On the other hand, twin studies 
provide strong evidence that a range of 
diverse smoking phenotypes—including 
age at initiation, intensity, nicotine depen-
dence (expressed by the Fagerstrom test), 
and cessation propensity—have a sub-
stantial hereditary component (Caporaso 
et al., 2009). Results from linkage analy-
sis studies have generally been hetero-
geneous and short on conclusive find-
ings. Gene association studies have been 
focused until recently on genes in a few 
candidate pathways, particularly genes 
in opioid, serotoninergic, dopaminergic, 
drug-metabolizing enzyme, and nico-
tinic and muscarinic cholinergic recep-
tor pathways. Results from these studies 
have been largely equivocal. Genome-
wide association studies may offer better 
information with which to identify causal 
relationships. A few such studies point to 
a region on chromosome 15q25.1, span-
ning the nicotinic acetylcholine receptors 
CHRNA5, CHRNA3, and CHRNB4, as 
being associated with smoking intensity 
(i.e., number of cigarettes smoked per 
day or dichotomized smoking intensity). 
Future research into the genetics of smok-
ing behavior should take into account the 
interaction between genetic influences 
and environmental factors, whereas stud-
ies focused on the role of smoke in dis-
ease causation should consider the genet-
ic component of smoking behavior.
What next?
Psoriasis is a phenotypically hetero-
geneous disorder, and our understanding 
of its clinical variations remains fragmen-
tary. Psoriatic arthritis, which represents 
an interesting conundrum of a “disease 
within a disease,” adds to its complexity. 
Epidemiologically, psoriatic arthritis is dif-
ficult to study because it is not easy to dis-
entangle whether the risk factors revealed 
are for the complete disease phenotype 
(arthritis and psoriasis) or for one of its 
components. Studies that compare psori-
atic arthritis patients with healthy controls 
are as yet not able to address this issue. A 
well-designed case–control study, how-
ever, should have the ability and power 
to separate the genetics of susceptibility 
to psoriatic arthritis from those of its con-
stituent parts by choosing, for example, 
different control groups simultaneously 
(such as a control group of patients who 
have psoriasis without arthritis and one 
with inflammatory arthritis without pso-
riasis). Large numbers would be required 
to allow subgroup analyses, stratifying the 
psoriatic arthritis data set for type of pso-
riasis and pattern of joint involvement. A 
study powered adequately to allow dis-
section of skin and joint involvement at a 
genetic level would be a major contribu-
tion to our understanding of the psoriasis–
arthritis connection. Smoking should be 
considered in these studies as a possible 
risk modifier. Moreover, as genetic stud-
ies of smoking behavior move forward, 
the possible roles of genes influencing 
smoking attitude and tobacco depen-
dence should be carefully considered.
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Adoptive cell Transfer in the 
Treatment of Metastatic Melanoma
Per thor Straten1 and Jürgen C. Becker2
Adoptive cell therapy (AcT) for metastatic cancer is the focus of considerable 
research effort. Rosenberg’s laboratory demonstrated a 50% response rate in stage IV 
melanoma patients treated with in vitro expanded tumor-infiltrating lymphocytes 
(TILs) and high-dose IL-2 administered after nonmyeloablative conditioning (Dudley 
et al., 2002a). Because early attempts to use expanded TILs in melanoma therapy failed 
to demonstrate better efficacy than high-dose IL-2 (Rosenberg et al., 1994), the effi-
cacy of TILs and nonmyeloablative conditioning in combination implies that patient 
conditioning is crucial to clinical success. The 2002 data represent a milestone in cel-
lular cancer therapy and a turning point for AcT in cancer treatment.
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Expansion of TILs for clinical use is 
labor intensive and requires a signifi-
cant investment in infrastructure, equip-
ment, and staff, as well as a high degree 
of expertise in both the clinic and the 
labor atory. This explains, at least in part, 
